CoChat

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates

Open access
Unzu, Carmen, Hervás-Stubbs, Sandra, Sampedro, Ana, Mauleón, Itsaso, Mancheño, Uxua, Alfaro, Carlos, de Salamanca, Rafael Enríquez, Benito, Alberto, Beattie, Stuart G, Petry, Harald, Prieto, Jesús, Melero, Ignacio, Fontanellas, Antonio · 2012 · Journal of Translational Medicine

Abstract

Background: Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. In humans, the cellular immune response poses a serious obstacle for transgene persistence while neutralizing humoral immunity curtails re-administration. Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria) benefits from liver gene transfer in mouse models and clinical trials are about to begin. In this work, we sought to study in non-human primates the feasibility of repeated gene-transfer with intravenous administration of rAAV5 vectors under the effects of an intensive immunosuppressive regimen and to analyze its ability to circumvent T-cell immunity and thereby prolong transgene expression. Methods: Three female Macaca fascicularis were intravenously injected with 1x10 13 genome copies/kg of rAAV5 encoding the human PBGD. Mycophenolate mofetil (MMF), anti-thymocyte immunoglobulin, methylprednisolone, tacrolimus and rituximab were given in combination during 12 weeks to block T- and B-cell mediated adaptive immune responses in two macaques. Immunodeficient and immunocompetent mice were intravenously injected with 5x10 12 genome copies/kg of rAAV5-encoding luciferase protein. Forty days later MMF, tacrolimus and rituximab were daily administrated to ascertain whether the immunosuppressants or their metabolites could interfere with transgene expression. Results: Macaques given a rAAV5 vector encoding human PBGD developed cellular and humoral immunity against viral capsids but not towards the transgene. Anti-AAV humoral responses were attenuated during 12 weeks but intensely rebounded following cessation of the immunosuppressants. Accordingly, subsequent gene transfer with a rAAV5 vector encoding green fluorescent protein was impossible. One macaque showed enhanced PBGD expression 25 weeks after rAAV5-pbgd administration but overexpression had not been detected while the animal was under immunosuppression. As a potential explanation, MMF decreases transgene expression in mouse livers that had been successfully transduced by a rAAV5 several weeks before MMF onset. Such a silencing effect was independent of AAV complementary strand synthesis and requires an adaptive immune system. Conclusions: These results indicate that our transient and intensive pharmacological immunosuppression fails to improve AAV5-based liver gene transfer in non-human primates. The reasons include an incomplete restraint of humoral immune responses to viral capsids that interfere with repeated gene transfer in addition to an intriguing MMF-dependent drug-mediated interference with liver transgene expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1479-5876-10-122

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 An immunosuppressive pharmacological regimen delays and weakens immunity against rAAV5 capsid antigens. A) Schematic timeline representation of the administration of two rAAV serotype 5 vectors in macaques under combined pharmacological immunosuppression. rAAV5-PBGD was injected first and rAAV5-egfp second. Animals are colour coded, identified by the NHP-digit code and their timeline represented by a horizontal arrow. B) Sequential follow-up of serum rAAV5 neutralizing antibodies in the serum of the colour-coded animals. C)In vitro mitogenic response of peripheral blood mononuclear cells (PBMC) at the indicated time points to rAAV5 capsids, measured by 3 H-Thy incorporation. D) Sequential follow-up of proviral rAAV5-PBGD DNA detection from serum samples of the colour-coded animals by quantitative PCR of vector DNA. Each dot represents the average of two independent measurements for each sample at a time point.
Figure 1 An immunosuppressive pharmacological regimen delays and weakens immunity against rAAV5 capsid antigens. A) Schematic timeline representation of the administration of two rAAV serotype 5 vectors in macaques under combined pharmacological immunosuppression. rAAV5-PBGD was injected first and rAAV5-egfp second. Animals are colour coded, identified by the NHP-digit code and their timeline represented by a horizontal arrow. B) Sequential follow-up of serum rAAV5 neutralizing antibodies in the serum of the colour-coded animals. C)In vitro mitogenic response of peripheral blood mononuclear cells (PBMC) at the indicated time points to rAAV5 capsids, measured by 3 H-Thy incorporation. D) Sequential follow-up of proviral rAAV5-PBGD DNA detection from serum samples of the colour-coded animals by quantitative PCR of vector DNA. Each dot represents the average of two independent measurements for each sample at a time point.CC BY · PubMed Central
Figure 2 Administration of second rAAV5 vector of the same serotype cannot achieve transgene expression even under immunosuppression of macaques with the five-drug regimen. A) Representative microphotographs of liver sections from the necropsy material of the indicated animals upon immunostaining with an anti-eGFP polyclonal antibody. The positive control animal (NHP004) received only a rAAV-egfp injection as indicated in Figure 1. B) mRNA analysis by RT-PCR corresponding to specific egfp mRNA expression in liver of colour-coded animals. Data are expressed as median ± standard deviation of eight different lobes in each macaque. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus naïve non-human primate.
Figure 2 Administration of second rAAV5 vector of the same serotype cannot achieve transgene expression even under immunosuppression of macaques with the five-drug regimen. A) Representative microphotographs of liver sections from the necropsy material of the indicated animals upon immunostaining with an anti-eGFP polyclonal antibody. The positive control animal (NHP004) received only a rAAV-egfp injection as indicated in Figure 1. B) mRNA analysis by RT-PCR corresponding to specific egfp mRNA expression in liver of colour-coded animals. Data are expressed as median ± standard deviation of eight different lobes in each macaque. *, p < 0.05; **, p < 0.01; ***, p < 0.001 versus naïve non-human primate.CC BY · PubMed Central
Figure 3 Transient pharmacological immunosuppression fails to enhance rAAV5-mediated gene transfer to the liver in macaques. A) Sequential follow-up of PBGD activity in homogenates from liver samples taken at the indicated time points. Normal range was defined as means ± 2 standard deviation of a separate group of four non-injected female macaques. B) Analyses of human PBGD mRNA content by quantitative RT-PCR in liver homogenates from necropsies taken at sacrifice (week 25). C) Immunohistochemistry detection of hepatocytes overexpressing PBGD on formalin-fixed and paraffin-embedded sections from liver biopsies obtained from the indicated animals at sacrifice. Data corresponding to necropsy samples (week 25) are expressed as median ± standard deviation of eight different lobes in each macaque.
Figure 3 Transient pharmacological immunosuppression fails to enhance rAAV5-mediated gene transfer to the liver in macaques. A) Sequential follow-up of PBGD activity in homogenates from liver samples taken at the indicated time points. Normal range was defined as means ± 2 standard deviation of a separate group of four non-injected female macaques. B) Analyses of human PBGD mRNA content by quantitative RT-PCR in liver homogenates from necropsies taken at sacrifice (week 25). C) Immunohistochemistry detection of hepatocytes overexpressing PBGD on formalin-fixed and paraffin-embedded sections from liver biopsies obtained from the indicated animals at sacrifice. Data corresponding to necropsy samples (week 25) are expressed as median ± standard deviation of eight different lobes in each macaque.CC BY · PubMed Central
Figure 4 Mycophenolate mofetil (MMF) interference with transgene expression in mice. A) Sequential follow-up by bioluminescence of hepatic luciferase expression following an i.v. dose of 5x1012 genome copies of rAAV5-luciferase/kg in BALB/c mice with or without immunosuppressants at the indicated time points. B) The left graph represents luciferase expression measured as bioluminescence in the livers of Rag−/−, Rag−/−IL-2Rγ−/− and wild type syngeneic BALB/c mice 3 weeks after vector administration. The right graph shows proviral DNA content assessed by quantitative PCR in the liver of the same animals. C) The left graph represents sequential follow-up of hepatic luciferase expression following rAAV5-luciferase/kg injection in BALB/c mice and Rag−/− mice. Four weeks following vector administration daily MMF was given for 15 days to the indicated groups. The right graph shows vector DNA quantification in the liver when mice were sacrificed three days after MMF cessation (45 days after vector infusion). ++, P < 0.01 versus wild type mice without immunosuppression.
Figure 4 Mycophenolate mofetil (MMF) interference with transgene expression in mice. A) Sequential follow-up by bioluminescence of hepatic luciferase expression following an i.v. dose of 5x1012 genome copies of rAAV5-luciferase/kg in BALB/c mice with or without immunosuppressants at the indicated time points. B) The left graph represents luciferase expression measured as bioluminescence in the livers of Rag−/−, Rag−/−IL-2Rγ−/− and wild type syngeneic BALB/c mice 3 weeks after vector administration. The right graph shows proviral DNA content assessed by quantitative PCR in the liver of the same animals. C) The left graph represents sequential follow-up of hepatic luciferase expression following rAAV5-luciferase/kg injection in BALB/c mice and Rag−/− mice. Four weeks following vector administration daily MMF was given for 15 days to the indicated groups. The right graph shows vector DNA quantification in the liver when mice were sacrificed three days after MMF cessation (45 days after vector infusion). ++, P < 0.01 versus wild type mice without immunosuppression.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 69

Metadata

Authors
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., Prieto, J., Melero, I., & Fontanellas, A.
Affiliations
  • Centro de Investigación Médica Aplicada (ES)
  • Clinica Universidad de Navarra (ES)
Corresponding author
Melero, Ignacio
Venue
Journal of Translational Medicine
Published
2012-06-15
Volume
10
Issue
1
Pages
122-122
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2146402993
Cited by
69
References
29
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 1 · 2015: 10 · 2014: 4 · 2013: 4
FWCI
3.45
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deposito Adademico Digital Universidad De Navarra (University of Navarra) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fundación Mutua Madrileña (RD06/0020)
  • European Commission (261506, 201842)
  • Fundación Científica Asociación Española Contra el Cáncer
  • Universidad de Navarra
  • Ministerio de Ciencia e Innovación (SAF2011-22831)
  • Gobierno de Navarra
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
Keywords
liver gene transfer, immunosuppression, porphobilinogen deaminase, acute intermittent porphyria, T cell immunity, humoral immunity, mycophenolate mofetil, tacrolimus, rituximab, non-human primates, macaque, immunocompetent mice
MeSH terms
Dependovirus, Animals, Antigens, Viral, Capsid, DNA, Viral, Female, Genetic Vectors, Humans, Immunity, Immunosuppression Therapy, Immunosuppressive Agents, Injections, Intravenous, Liver, Macaca fascicularis, Mice, Transgenic, Mycophenolic Acid, Serotyping, Treatment Failure, Gene Transfer Techniques, Transgenes, Mice, Immunity, Humoral

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. https://app.cochat.ai/papers/10.1186/1479-5876-10-122
The paper
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., Prieto, J., Melero, I., & Fontanellas, A. (2012). Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-10-122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.